21 results about "Shingles" patented technology

Described are modified Varicella Zoster Virus glycoprotein E (VZV gE) proteins having improved stability and / or immunogenicity compared to a non-modified VZV gE. Also described are associated nucleic acids, immunogenic compositions, and methods of using such modified VZV gE proteins in the treatment or prevention of shingles.

The invention relates to the field of medical auxiliary instruments, in particular to a herpes zoster smearing administration device which comprises a medicine squeezing barrel and an air blowing assembly arranged on one side of the medicine squeezing barrel. The bottom of the medicine extruding barrel is connected with a medicine discharging piece, the medicine extruding barrel extrudes to drive medicine to be flatly spread and extruded from an outlet of the medicine discharging piece in a rectangular shape, and an air outlet of the air blowing assembly is located in one side of the outlet of the medicine discharging piece. According to the device, through the arranged medicine outlet piece, medicine can be sent out from a fixed position, due to the fact that the medicine outlet position is rectangular, the extruded medicine can be in a thin-layer tiled state, for ointment type medicine, the uniform smearing function can be achieved, then the air blowing assembly is assisted to blow air to the tiled medicine, and therefore the medicine can be evenly smeared. The medicine is better attached to the skin through wind pressure, so that it is guaranteed that the medicine makes full contact with the skin, the problem of varicella rupture can be avoided only by controlling the wind speed and the wind pressure during blowing, and the safety risk caused by manual operation can be effectively avoided.

To provide herpes zoster mRNA vaccine, a preparation method therefor, and use thereof.SOLUTION: Provided is a herpes zoster mRNA vaccine, comprising an RNA encoding a varicella-zoster virus gE glycoprotein or a variant thereof, wherein the vaccine can prevent herpes zoster infection and its complications.SELECTED DRAWING: Figure 2

To provide herpes zoster mRNA vaccine, a preparation method therefor, and use thereof.SOLUTION: Provided is a herpes zoster mRNA vaccine, comprising an RNA encoding a varicella-zoster virus gE glycoprotein or a variant thereof, wherein the vaccine can prevent herpes zoster infection and its complications.SELECTED DRAWING: Figure 2

The present disclosure provides a traditional Chinese medicine composition for treating herpes zoster and a preparation method thereof, and relates to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition includes the following components by weight: 20-40 portions of radix bupleuri, 30-50 portions of radix scutellariae, 10-20 portions of rhizoma pinelliae preparata, 30-50 portions of radix paeoniae rubra, 20-40 portions of stir-fried fructus aurantii, 20-40 portions of radix rhapontici, 20-40 portions of fructus forsythiae, 50-70 portions of poria cum radix pini, 10-30 portions of radix angelicae sinensis and 40-60 portions of rhizoma zingiberis recens. The present disclosure reasonably controls the content ratio of specific components of each traditional Chinese medicine and optimizes the preparation method, so that the obtained traditional Chinese medicine composition has a better therapeutic effect on herpes zoster.

This invention discloses a traditional Chinese medicine composition for the prevention and / or treatment of herpes and / or its complications. By weight, the composition comprises: 8-14 parts of Sophora flavescens, 5-11 parts of Bistorta officinalis, 9-15 parts of Rheum palmatum, 0.5-6 parts of Coptis chinensis, 1-7 parts of Forsythia suspensa, 1-7 parts of Taraxacum mongolicum, 1-7 parts of Viola yedoensis, 1-7 parts of Paeonia lactiflora, 1-7 parts of Paeonia suffruticosa, 1-7 parts of Gardenia jasminoides, 3-9 parts of Rehmannia glutinosa, 1-7 parts of Chrysanthemum indicum, 1-7 parts of Lonicera japonica, 1-7 parts of Atractylodes lancea, 0.5-6 parts of Phellodendron chinense, 0.5-1.5 parts of Cicadae periostracum, 2-8 parts of Smilax glabra, 1-7 parts of Anemarrhena asphodeloides, 1-7 parts of Ophiopogon japonicus, 0.5-6 parts of Alisma plantago-aquatica, and 1-7 parts of Gypsum fibrosum. The complications are pain and / or inflammation. This traditional Chinese medicine composition is safe, effective, and has a simple and efficient preparation method with controllable quality. It also exhibits significant analgesic and anti-inflammatory effects and can treat shingles and its sequelae.

The present invention relates to the technical field of emulsification equipment, specifically to an emulsification equipment for preparing shingles vaccine, comprising a fixed cylinder, and also comprising: a mixing mechanism, arranged inside the fixed cylinder, for counter-mixing an upper solution with a bottom solution, which comprises an upper liquid path component and a bottom liquid path component; a power mechanism, arranged in the fixed cylinder, for driving the mixing mechanism to operate; a middle fixed cylinder, fixedly installed inside the fixed cylinder, a stator being provided at the bottom thereof, a rotor being rotatably configured in the stator, and the device is provided with a mixing mechanism, by arranging multiple liquid outlet nozzles on the inner side of an annular space formed by multiple vertical connecting pipe arrays, the upper liquid is sprayed out from the liquid spray short pipe, and the bottom liquid is sprayed out from the liquid outlet nozzle, and the two collide on the side of the stator to form a mixed liquid. Compared with traditional single stirring, it can achieve full contact between substances of different properties, greatly improve the mixing uniformity, and effectively avoid the stratification problem caused by uneven distribution of components.

In an embodiment, the invention is directed to prodrug compounds of L-BHDU according to the chemical structure I:Where R1 is a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group;R2 is H, a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok— R2a group;R1a is independently a C6-C30alkyl group, often a C12-C22 alkyl group, often a C14-C20 alkyl group or a C16-C18 alkyl group, often a C16 or C18 alkyl group;R2a is independently a C1-C12 alkyl group, often a C2-C6 alkyl group, a C3-C4 alkyl group, an isopropyl, t-butyl or sec-butyl group, or an isopropyl or t-butyl group;Each j is independently 1-6, 1-3, often 1 or 2;Each k is 0 or 1;Each n is independently 1-6, 1-4, 2-4 or 2 or 3; orA pharmaceutically acceptable salt, solute or polymorph thereof. Additional embodiments are directed to pharmaceutical compositions based upon the disclosed chemical compounds and methods of treating or reducing the likelihood of VZV, HSV-1 or HSV-2 infections. Methods of synthesizing compounds according to the present invention represent further embodiments of the invention.

The present disclosure relates to circular RNA sequences encoding an antigen from varicella zoster virus (VZV). The circular RNA sequences described herein are used as vaccines and compositions for preventing or treating diseases resulting from VZV, including shingles. Methods of use, including methods of treating or preventing a disease caused by VZV and methods for formulating and preparing the VZV vaccine compositions, are also described.

The present disclosure relates to immunogenic compositions comprising a varicella zoster vims (VZV) glycoprotein E antigen and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against VZV in an individual in need thereof.

The utility model belongs to the technical field of supporting structures, and particularly relates to an inner supporting structure for a herpes zoster patient to wear, which comprises a supporting piece, the supporting piece is composed of a fixing buckle A, a fixing buckle B, a first supporting rod, a second supporting rod, a fixing seat and a mounting seat, the fixing buckle A is matched and connected with a lock cylinder in the fixing buckle B through a pin arranged on the fixing buckle A, and the first supporting rod is connected with the second supporting rod through a pin arranged on the mounting seat. The fixing buckle A is connected with the first supporting rod, the second supporting rod is inserted into the first supporting rod and movably connected with the first supporting rod, a clamping hole is formed in the first supporting rod, the clamping hole is connected with a spring clamping block arranged on the second supporting rod in a clamped mode, the first supporting rod is connected with the fixing base, and the fixing base is connected with the second supporting rod. An inserting groove is formed in the fixing base, the inserting groove is connected with an inserting strip arranged on the mounting base in an inserted mode, and mucilage glue used for being adhered to the human body is further arranged on the mounting base, so that the clothes hanger is small, light, convenient and easy to use, clothes can be prevented from making contact with herpes, and use convenience can be improved.

The present disclosure relates to mRNA sequences encoding an antigen from varicella zoster virus. The mRNA sequences described herein are used as vaccines and compositions for preventing or treating diseases resulting from varicella zoster virus, including shingles. Methods for formulating and preparing the vaccines are also described.

This disclosure describes a cannabinoid-based nanoplatform for treating shingles, designed to enhance bioavailability and controlled release of active ingredients. The composition includes cannabinoids like cannabidiol (CBD) and cannabigerol (CBG), alongside flavonoids, polyphenols, and alkaloids, in oral and topical formulations. The oral capsule combines cannabinoids with polyphenols and flavonoids to provide systemic anti-inflammatory, antiviral, and neuroprotective effects, particularly for nerve pain and inflammation, including postherpetic neuralgia. The topical cream includes cannabinoids, capsaicin, and aloe vera, offering localized relief from pain, itching, and rash. The method targets both systemic and localized symptoms during the acute phase of shingles, aiming to inhibit varicella-zoster virus replication, disrupt viral assembly, and prevent viral release, while also providing immune modulation and anti-inflammatory benefits. The nanoplatform uses nano-emulsification techniques, producing particles smaller than 200 nm to ensure optimal delivery and therapeutic efficacy, offering comprehensive relief for shingles symptoms.

This invention provides a traditional Chinese medicine composition for treating herpes zoster, its preparation method, and its application, belonging to the field of traditional Chinese medicine technology. The active ingredients of the traditional Chinese medicine composition include the following two parts: (1) Traditional Chinese medicine active ingredients: by weight, prepared from the following traditional Chinese medicinal materials: 10-15 parts of Isatis root; 10-15 parts of Isatis leaf; 10-15 parts of Astragalus; 8-12 parts of Angelica sinensis; 8-12 parts of white peony root; 6-10 parts of Ligusticum chuanxiong; 5-8 parts of safflower; 5-8 parts of red peony root; 5-8 parts of Salvia miltiorrhiza; 4-7 parts of cicada slough; 4-7 parts of earthworm; 4-7 parts of Saposhnikovia divaricata; and 3-5 parts of licorice; (2) Western medicine active ingredients: composed of acyclovir and famciclovir in a weight ratio of 1:1-3. This invention is a traditional Chinese and Western medicine combined drug developed based on the traditional Chinese medicine treatment of herpes zoster and combined with modern pharmaceutical technology. It adopts bio-enzymatic hydrolysis technology and nano-level drug delivery system, which significantly improves the bioavailability and targeting of the drug. It has a unique therapeutic effect on shingles, and its advanced preparation process results in significant efficacy, short onset time, convenient administration, few adverse reactions, safety and effectiveness. It can also prevent and relieve postherpetic neuralgia, providing a new option for the treatment of shingles.

The present application relates to compositions capable of inducing an immune response against Varicella zoster virus, methods of administering such compositions, and methods of producing such compositions.

The present disclosure relates to compositions of nucleic acid vaccines comprising polynucleotide sequences encoding one or more structural proteins of varicella-zoster virus (VZV) and methods of making, making and therapeutic uses for treating, alleviating, ameliorating and / or preventing herpes zoster.

The present disclosure relates to mRNA sequences encoding an antigen from varicella zoster virus. The mRNA sequences described herein are used as vaccines and compositions for preventing or treating diseases resulting from varicella zoster virus, including shingles. Methods for formulating and preparing the vaccines are also described.

The present invention relates to an ethanol extract of phytotherapeutic origin, from the Spilanthes americana (Acmella oppositifolia) plant and the Matricaria chamomilla plant, which acts directly on mouth ulcers, cold sores and shingles. The extract is for medical or odontological use, is composed of an ethanol extract with a vehicle to provide a cream dosage form, and works topically in the form of a rinse or cream, producing an antiviral effect in the prodrome, thereby preventing the onset of symptoms and the development of vesicles, pain and sores caused by viral herpes infection. If vesicles are present, the progression time is significantly reduced, enabling swift recovery.

The invention discloses varicella zoster intravenous injection human immune globulin and a preparation process thereof. The preparation process comprises the following steps: (1) preparing cryoprecipitate-free plasma; (2) preparing a component II + III precipitate; (3) performing impurity protein precipitation treatment, and then adding polyethylene glycol 4000 to perform impurity precipitation treatment; (4) carrying out ultrafiltration dialysis treatment, and then carrying out cation exchange chromatography column elution purification treatment; (5) carrying out ultrafiltration dialysis treatment, and then carrying out mixed mode chromatographic column purification treatment; (6) carrying out ultrafiltration dialysis treatment on the flow-through liquid by using a stabilizer buffer solution containing histidine and cane sugar; and (7) sterilizing, filtering and inactivating viruses to obtain the protein fluid containing the varicella-zoster intravenous injection human immune globulin. According to the process disclosed by the invention, the purity of the final product is stabilized at 99.5% or above, the PKA content is lower than 5 IU / ml, the varicella zoster antibody titer is higher than 25 IU / ml, all indexes of an accelerated stability test meet and are far superior to those of domestic and overseas pharmacopoeia standards, and a safer and more effective treatment choice is provided for clinic.